(Research Triangle Park, N.C. and New Orleans, La.) ClinPharm Consulting, a specialized consulting firm offering a unique paradigm for empowering drug development pipelines, has announced its participation in the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, Louisiana November 14-18.

For the first time in its history, the AAPS Annual Meeting is combining with the International Pharmaceutical Federation’s Pharmaceutical Sciences World Congress to create a seminal event for sharing advances in pharmaceutical sciences. Already billed as the world’s largest gathering of pharmaceutical scientists, the new format to the event is expected to draw approximately 2,000 additional scientists and life sciences professionals to the 10,000+ attendee event.

“As exemplified by the changes to the AAPS Annual Meeting, the biopharmaceutical industry continues to evolve,” ClinPharm Consulting President Geoffrey Banks, Ph.D., said, adding, “It’s important that ClinPharm is an active participant in this conference to keep up-to-date with breakthrough research and technologies, and share what we’re learning about the traditional biopharma business model becoming obsolete.”

According to Dr. Banks, the fluid nature of today’s emerging and virtual drug development firms is calling more and more for specialized, cost-effective expertise horizontally integrated across entire early-phase drug development programs, unlike the individual vertical services (e.g., conducting a single study) typically offered by contract research organizations..

“There are numerous moving parts to the drug development pipeline that can create pitfalls for small biopharmaceutical companies with minimal R&D infrastructure. We are finding an unmet need within these organizations for an integrated resource to help them deal with the myriad of PK/PD, clinical, and commercial challenges,” Dr. Banks said.

ClinPharm Consulting is exhibiting at the event to showcase its unique combination of horizontally integrated services across a drug development program incorporating the firm’s PK/PD expertise, medical/scientific writing skills, and complete understanding of clinical pharmacology from a scientific, regulatory, and clinical conduct perspective which is unmatched in the industry.

The event features over 100 programming sessions including concentrated short courses, symposia, roundtables, sunrise sessions and more than 2,500 contributed papers covering the latest research in pharmaceutical sciences. Topics to be addressed include global health, medicinal chemistry, model-based drug development, and nanotechnology, among others.

ClinPharm Consulting has been steadily growing its portfolio of emerging and virtual drug development firms who are seeking assistance from the firm’s team of credentialed industry veterans to position their drug development programs for success.

For more information on ClinPharm Consulting services, email discover@clinpharmconsulting.com or visit www.clinpharmconsulting.com.

ABOUT CLINPHARM CONSULTING
ClinPharm Consulting is a specialized consulting firm offering a unique paradigm for empowering drug development pipelines. Our business model focuses on matching scientific and pharmacokinetic/pharmacodynamic expertise with superior writing capabilities to maximize the impact of individual studies on an overall clinical pharmacology program. We specialize in helping small biopharmaceutical companies with minimal R&D infrastructure find scalable solutions for emerging early phase drug development challenges, providing an unmatched combination of technical expertise and robust understanding of clinical pharmacology from a scientific, regulatory and clinical conduct perspective.

The breadth of our experience allows ClinPharm Consulting to be a complete resource for clients to set up their drug development programs for success. ClinPharm Consulting typically engages clients as early as the IND planning stage to develop robust clinical pharmacology strategies and then works as a horizontally integrated, in-house resource to assist with the execution and analysis of those strategies. Our efforts not only include the design, conduct, and analysis of clinical pharmacology studies but also helping clients transition from nonclinical research into early phase clinical trials as well as transitioning from healthy volunteers into patients with the target disease.